MediWound Announces Peer-Reviewed Publication Of EscharEx Mechanism Of Action Study Assessing Its Effects On Biofilm And Microbial Loads
Portfolio Pulse from Benzinga Newsdesk
MediWound Ltd. (NASDAQ:MDWD) announced the publication of a study in WOUNDS Journal on EscharEx, a debridement agent for chronic wounds. The study showed EscharEx effectively debrides wounds, reduces biofilm and bacterial load, and is safe. The Phase II study results are promising for VLUs and DFUs treatment, with a Phase III study planned for the second half of 2024.
December 21, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediWound's EscharEx shows positive Phase II results in debriding chronic wounds and reducing biofilm/bacterial load, with a Phase III study set for 2H 2024.
The positive results from the Phase II study of EscharEx suggest potential for regulatory approval and market adoption, which could drive MediWound's revenue growth and positively impact stock price in the short term. The announcement of a forthcoming Phase III study further reinforces the potential for future growth, making this news highly relevant and important for investors. The confidence score is high due to the clear positive outcomes of the study and the direct impact on MediWound's product pipeline.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100